Fig. 2

Survival of patients according to clinical characteristics. a Patients with < 3 brain metastases (BMs) showed survival advantage compared with those with > 3 BMs (25 (193.4–30.6) vs. 9 (6.9–11.1) months, P < 0.001). b Patients with ECOG score ≤ 2 showed a survival advantage compared with those with ECOG > 2 (21 (14.8–27.2) vs. 7 (3.8–10.2), P < 0.001). c After BMs, the median survival of the four groups of treatment was 20 (range, 6.0–34.0) months for radiotherapy, 9 (range, 7.0–11.1) months for chemotherapy, 12 (range, 5.7–18.3) months for targeted therapy, and 25 (range, 16.7–33.3) months for targeted therapy combined with radiotherapy (P < 0.05). d The median intracranial progression-free survival (iPFS) among the four treatments was 12 (range, 0–24.6) months for radiotherapy, 7 (range, 2.5–11.5) months for chemotherapy, 10 (range, 5.3–14.7) months for targeted therapy, and 21 (range, 14.0–28.0) months for targeted therapy combined with radiotherapy (P < 0.05)